CHRS Q2 2021 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$219M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$88M-35.4% YoY

Gross Profit

$71M80.9% margin

Operating Income

-$24M-27.6% margin

Net Income

-$30M-34.1% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

+5.6%

Cash Flow

Operating Cash Flow

-$188,000

Free Cash Flow

-$603,000

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$740M

Total Liabilities

$583M

Stockholders' Equity

$156M

Cash & Equivalents

$330M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$88M	$136M	-35.4%
Gross Profit	$71M	$126M	-43.5%
Operating Income	-$24M	$65M	-137.0%
Net Income	-$30M	$59M	-150.7%

Revenue Segments

Product

$88M100%